Lilly to Appeal After UK Agency Opposes Reimbursement for Alzheimer’s Drug

Dismay but little surprise as NICE rejects Alzheimer's drugs

Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again

Lilly to appeal after UK agency opposes reimbursement for Alzheimer’s drug

(Reuters) -Eli Lilly said on Thursday it would appeal against a UK agency’s recommendation to not reimburse the cost of Alzheimer’s drug Kisunla, blocking access for patients seeking treatment under the country’s state-run health service. The U.S.-based drugmaker plans to appeal on the grounds that the National Institute for Health and Care Excellence’s (NICE) recommendation was unreasonable based on the evidence the company, clinical experts an…

U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service

The NICE ruling means that the drugs, the first that can slow the decline caused by Alzheimer's, won't be available through the NHS.

HKBU-led research develops novel drug delivery system for Gouteng compound for Alzheimer’s disease treatment

HKBU-led research develops novel drug delivery system for Gouteng compound for Alzheimer’s disease treatment